Aminoquinolinones useful as CD38 inhibitors

What is AI technical title?
AI technical title is built by PatSnap AI team. It summarizes the technical point description of the patent document.
Aminoquinolinones are developed to inhibit CD38, addressing the need for treating metabolic and other disorders by increasing cellular NAD levels, effectively managing conditions like obesity and diabetes.

WO2026143049A1PCT designated stage Publication Date: 2026-07-02NEOLAIA INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner: NEOLAIA INC
Filing Date: 2025-12-22
Publication Date: 2026-07-02

Application Information

Patent Timeline

22 Dec 2025

Application

02 Jul 2026

Publication

WO2026143049A1

IPC: C07D401/04; C07D401/14; C07D405/14; C07D409/14; C07D417/04; C07D417/14; A61P35/00; A61K31/4704

AI Tagging

Technology Topics

DiseaseQuinoline

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure US2025060994_02072026_PF_FP_ABST

Patent Text Reader

Abstract

The present invention relates to compounds that have activity as cluster of differentiation 38 (CD38) inhibitors, compositions of such compounds, and methods using such compounds for preventing or treating diseases and disorders such as, for example, diseases and disorders of metabolism.

Need to check novelty before this filing date? Find Prior Art